Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$3.83
-0.54-12.36%
At close: -
$4.52
0.6918.02%
After Hours: 8:31 AM EDT
Comments
Loading...
Contineum Therapeutics Analyst Ratings and Price Targets | NASDAQ:CTNM | Benzinga
Contineum Therapeutics Inc has a consensus price target of $23.8 based on the ratings of 5 analysts. The high is $31 issued by RBC Capital on May 15, 2025. The low is $16 issued by Baird on March 7, 2025. The 3 most-recent analyst ratings were released by Morgan Stanley, RBC Capital, and Jones Trading on May 19, 2025, May 15, 2025, and March 13, 2025, respectively. With an average price target of $24.67 between Morgan Stanley, RBC Capital, and Jones Trading, there's an implied 445.72% upside for Contineum Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Morgan Stanley
RBC Capital
Jones Trading
Baird
Stifel
1calculated from analyst ratings
Analyst Ratings for Contineum Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/19/2025 | Buy Now | 342.48% | Morgan Stanley | Jeffrey Hung50% | $25 → $20 | Maintains | Overweight | Get Alert |
| 05/15/2025 | Buy Now | 585.84% | RBC Capital | Brian Abrahams48% | $31 → $31 | Reiterates | Outperform → Outperform | Get Alert |
| 03/13/2025 | Buy Now | 408.85% | Jones Trading | Debanjana Chatterjee27% | → $23 | Initiates | → Buy | Get Alert |
| 03/07/2025 | Buy Now | 453.1% | Morgan Stanley | Jeffrey Hung50% | $25 → $25 | Assumes | → Overweight | Get Alert |
| 03/07/2025 | Buy Now | 253.98% | Baird | Joel Beatty66% | $32 → $16 | Maintains | Outperform | Get Alert |
| 01/09/2025 | Buy Now | 585.84% | RBC Capital | Brian Abrahams48% | $31 → $31 | Reiterates | Outperform → Outperform | Get Alert |
| 11/07/2024 | Buy Now | 585.84% | RBC Capital | Brian Abrahams48% | $32 → $31 | Maintains | Outperform | Get Alert |
| 10/22/2024 | Buy Now | 607.96% | Baird | Joel Beatty66% | → $32 | Initiates | → Outperform | Get Alert |
| 08/14/2024 | Buy Now | 607.96% | RBC Capital | Brian Abrahams48% | $30 → $32 | Maintains | Outperform | Get Alert |
| 04/30/2024 | Buy Now | 541.59% | Stifel | Paul Matteis43% | → $29 | Initiates | → Buy | Get Alert |
| 04/30/2024 | Buy Now | 563.72% | RBC Capital | Brian Abrahams48% | → $30 | Initiates | → Outperform | Get Alert |
| 04/30/2024 | Buy Now | 453.1% | Morgan Stanley | Jeffrey Hung50% | → $25 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Contineum Therapeutics (CTNM) stock?
The latest price target for Contineum Therapeutics (NASDAQ:CTNM) was reported by Morgan Stanley on May 19, 2025. The analyst firm set a price target for $20.00 expecting CTNM to rise to within 12 months (a possible 342.48% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Contineum Therapeutics (CTNM)?
The latest analyst rating for Contineum Therapeutics (NASDAQ:CTNM) was provided by Morgan Stanley, and Contineum Therapeutics maintained their overweight rating.
When was the last upgrade for Contineum Therapeutics (CTNM)?
There is no last upgrade for Contineum Therapeutics
When was the last downgrade for Contineum Therapeutics (CTNM)?
There is no last downgrade for Contineum Therapeutics.
When is the next analyst rating going to be posted or updated for Contineum Therapeutics (CTNM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Contineum Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Contineum Therapeutics was filed on May 19, 2025 so you should expect the next rating to be made available sometime around May 19, 2026.
Is the Analyst Rating Contineum Therapeutics (CTNM) correct?
While ratings are subjective and will change, the latest Contineum Therapeutics (CTNM) rating was a maintained with a price target of $25.00 to $20.00. The current price Contineum Therapeutics (CTNM) is trading at is $4.52, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
